论文部分内容阅读
本文通过对Ara—C药代动力学研究及40例白血病患儿临床观察,试图研究Ara—C的作用机理及比较Ara-C对AML和ALL缓解(CR)率的影响。临床资料:40例病例中,男23例,女17例;年龄2岁～12岁,中位年龄6.5岁。其中AML17例,ALL23例,40例均为初治。治疗前,外周血白细胞17～21.2 3<10~9/L。多数为4.0×10~9/L;骨髓增生度:增生低下26例,活跃4例,明显活跃6例、极度活跃4例。AML组用COAP、HOAP方案,M_3用维甲酸治疗。ALL组用COAP、HOAP、AD+L-ASP。Ara—C的用量为100～200mg/m~2,用药时间为每一疗程5
In this paper, Ara-C pharmacokinetic study and 40 cases of leukemia clinical observation, trying to study the mechanism of Ara-C and compare Ara-C on AML and ALL CR rate. Clinical data: 40 cases, 23 males and 17 females; aged 2 to 12 years old, the median age of 6.5 years old. Of which AML17 cases, ALL23 cases, 40 cases were untreatment. Before treatment, peripheral blood leukocytes 17 ~ 21.2 3 <10 ~ 9 / L. Most of 4.0 × 10 ~ 9 / L; myeloid hyperplasia: hyperplasia in 26 cases, 4 cases were active, significantly active in 6 cases, extremely active in 4 cases. AML group with COAP, HOAP program, M_3 treatment with retinoic acid. ALL group with COAP, HOAP, AD + L-ASP. Ara-C dosage of 100 ~ 200mg / m ~ 2, medication time for each course of 5